Meningococcal Conjugate and tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccination Among HIV-Infected Youth

for the LEGACY Consortium

Research output: Contribution to journalArticle

Abstract

BACKGROUND:: The meningococcal conjugate vaccine (MCV4) and the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) were first recommended for adolescents in the United States in 2005. The goal of our study was to determine MCV4 & Tdap vaccines coverage among perinatally and behaviorally HIV-infected adolescents in 2006 and to compare coverage estimates in our study population to similarly aged healthy youth in 2006. METHODS:: LEGACY is a retrospective cohort study of HIV-infected youth in 22 HIV specialty clinics across the United States. Among LEGACY participants ≥11 years of age in 2006, we conducted a cross–sectional analysis to determine MCV4, Tdap, and MCV4/Tdap vaccine coverage. We compared vaccine coverage among our study population to coverage among similarly aged youth in the 2006 NIS-Teen Survey. Multivariable mixed effects logistic regression modeling was used to examine associations between MCV4/Tdap vaccination and mode of HIV transmission. RESULTS:: MCV4 and Tdap coverage rates among 326 eligible participants were 31.6% and 28.8% respectively. Among adolescents 13-17 years of age, MCV4 and Tdap coverage was significantly higher among HIV-infected youth than among youth in the 2006 NIS-Teen Survey (p 400 copies/ml were significantly less likely to have received MCV4/Tdap vaccination (p<0.05). CONCLUSIONS:: MCV4 and Tdap coverage among HIV-infected youth was suboptimal but higher than for healthy adolescents in the 2006 NIS-Teen Survey. Perinatal HIV infection was associated with increased likelihood of vaccination. Specific measures are needed to improve vaccine coverage among adolescents in the United States.

Original languageEnglish (US)
JournalPediatric Infectious Disease Journal
DOIs
StateAccepted/In press - Feb 5 2016

Fingerprint

Diphtheria Toxoid
Tetanus Toxoid
Whooping Cough
Acellular Vaccines
Pertussis Vaccine
Vaccination
Toxoids
HIV
Vaccines
Meningococcal Vaccines
Conjugate Vaccines

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases
  • Microbiology (medical)

Cite this

@article{479667acb838489a91040d536b149090,
title = "Meningococcal Conjugate and tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccination Among HIV-Infected Youth",
abstract = "BACKGROUND:: The meningococcal conjugate vaccine (MCV4) and the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) were first recommended for adolescents in the United States in 2005. The goal of our study was to determine MCV4 & Tdap vaccines coverage among perinatally and behaviorally HIV-infected adolescents in 2006 and to compare coverage estimates in our study population to similarly aged healthy youth in 2006. METHODS:: LEGACY is a retrospective cohort study of HIV-infected youth in 22 HIV specialty clinics across the United States. Among LEGACY participants ≥11 years of age in 2006, we conducted a cross–sectional analysis to determine MCV4, Tdap, and MCV4/Tdap vaccine coverage. We compared vaccine coverage among our study population to coverage among similarly aged youth in the 2006 NIS-Teen Survey. Multivariable mixed effects logistic regression modeling was used to examine associations between MCV4/Tdap vaccination and mode of HIV transmission. RESULTS:: MCV4 and Tdap coverage rates among 326 eligible participants were 31.6{\%} and 28.8{\%} respectively. Among adolescents 13-17 years of age, MCV4 and Tdap coverage was significantly higher among HIV-infected youth than among youth in the 2006 NIS-Teen Survey (p 400 copies/ml were significantly less likely to have received MCV4/Tdap vaccination (p<0.05). CONCLUSIONS:: MCV4 and Tdap coverage among HIV-infected youth was suboptimal but higher than for healthy adolescents in the 2006 NIS-Teen Survey. Perinatal HIV infection was associated with increased likelihood of vaccination. Specific measures are needed to improve vaccine coverage among adolescents in the United States.",
author = "{for the LEGACY Consortium} and Setse, {Rosanna W.} and Siberry, {George K.} and Moss, {William J} and John Wheeling and Bohannon, {Beverly A.} and Dominguez, {Kenneth L.}",
year = "2016",
month = "2",
day = "5",
doi = "10.1097/INF.0000000000001078",
language = "English (US)",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Meningococcal Conjugate and tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccination Among HIV-Infected Youth

AU - for the LEGACY Consortium

AU - Setse, Rosanna W.

AU - Siberry, George K.

AU - Moss, William J

AU - Wheeling, John

AU - Bohannon, Beverly A.

AU - Dominguez, Kenneth L.

PY - 2016/2/5

Y1 - 2016/2/5

N2 - BACKGROUND:: The meningococcal conjugate vaccine (MCV4) and the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) were first recommended for adolescents in the United States in 2005. The goal of our study was to determine MCV4 & Tdap vaccines coverage among perinatally and behaviorally HIV-infected adolescents in 2006 and to compare coverage estimates in our study population to similarly aged healthy youth in 2006. METHODS:: LEGACY is a retrospective cohort study of HIV-infected youth in 22 HIV specialty clinics across the United States. Among LEGACY participants ≥11 years of age in 2006, we conducted a cross–sectional analysis to determine MCV4, Tdap, and MCV4/Tdap vaccine coverage. We compared vaccine coverage among our study population to coverage among similarly aged youth in the 2006 NIS-Teen Survey. Multivariable mixed effects logistic regression modeling was used to examine associations between MCV4/Tdap vaccination and mode of HIV transmission. RESULTS:: MCV4 and Tdap coverage rates among 326 eligible participants were 31.6% and 28.8% respectively. Among adolescents 13-17 years of age, MCV4 and Tdap coverage was significantly higher among HIV-infected youth than among youth in the 2006 NIS-Teen Survey (p 400 copies/ml were significantly less likely to have received MCV4/Tdap vaccination (p<0.05). CONCLUSIONS:: MCV4 and Tdap coverage among HIV-infected youth was suboptimal but higher than for healthy adolescents in the 2006 NIS-Teen Survey. Perinatal HIV infection was associated with increased likelihood of vaccination. Specific measures are needed to improve vaccine coverage among adolescents in the United States.

AB - BACKGROUND:: The meningococcal conjugate vaccine (MCV4) and the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) were first recommended for adolescents in the United States in 2005. The goal of our study was to determine MCV4 & Tdap vaccines coverage among perinatally and behaviorally HIV-infected adolescents in 2006 and to compare coverage estimates in our study population to similarly aged healthy youth in 2006. METHODS:: LEGACY is a retrospective cohort study of HIV-infected youth in 22 HIV specialty clinics across the United States. Among LEGACY participants ≥11 years of age in 2006, we conducted a cross–sectional analysis to determine MCV4, Tdap, and MCV4/Tdap vaccine coverage. We compared vaccine coverage among our study population to coverage among similarly aged youth in the 2006 NIS-Teen Survey. Multivariable mixed effects logistic regression modeling was used to examine associations between MCV4/Tdap vaccination and mode of HIV transmission. RESULTS:: MCV4 and Tdap coverage rates among 326 eligible participants were 31.6% and 28.8% respectively. Among adolescents 13-17 years of age, MCV4 and Tdap coverage was significantly higher among HIV-infected youth than among youth in the 2006 NIS-Teen Survey (p 400 copies/ml were significantly less likely to have received MCV4/Tdap vaccination (p<0.05). CONCLUSIONS:: MCV4 and Tdap coverage among HIV-infected youth was suboptimal but higher than for healthy adolescents in the 2006 NIS-Teen Survey. Perinatal HIV infection was associated with increased likelihood of vaccination. Specific measures are needed to improve vaccine coverage among adolescents in the United States.

UR - http://www.scopus.com/inward/record.url?scp=84957709957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957709957&partnerID=8YFLogxK

U2 - 10.1097/INF.0000000000001078

DO - 10.1097/INF.0000000000001078

M3 - Article

C2 - 26855409

AN - SCOPUS:84957709957

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

ER -